New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Protein-protein interactions (PPIs) are fundamental to cellular signaling and transduction which marks them as attractive therapeutic drug development targets. What were once considered to be undruggable targets have become increasingly feasible due to the progress that has been made over the last two decades and the rapid technological advances. This work explores the influence of technological innovations on PPI research and development. Additionally, the diverse strategies for discovering, modulating, and characterizing PPIs and their corresponding modulators are examined with the aim of presenting a streamlined pipeline for advancing PPI-targeted therapeutics. By showcasing carefully selected case studies in PPI modulator discovery and development, we aim to illustrate the efficacy of various strategies for identifying, optimizing, and overcoming challenges associated with PPI modulator design. The valuable lessons and insights gained from the identification, optimization, and approval of PPI modulators are discussed with the aim of demonstrating that PPI modulators have transitioned beyond early-stage drug discovery and now represent a prime opportunity with significant potential. The selected examples of PPI modulators encompass those developed for cancer, inflammation and immunomodulation, as well as antiviral applications. This perspective aims to establish a foundation for the effective targeting and modulation of PPIs using PPI modulators and pave the way for future drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Accurate structure prediction of biomolecular interactions with AlphaFold 3
Abramson, J., Adler, J., Dunger, J., Evans, R., Green, T., Pritzel, A., Ronneberger, O., Willmore, L., Ballard, A. J., Bambrick, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07487-w · Cited by 15,861
Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan, D., Stroe, O., Wood, G., Laydon, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1061 · Cited by 7,850
Accurate prediction of protein structures and interactions using a 3-track network
Baek, M., DiMaio, F., Anishchenko, I., Dauparas, J., Ovchinnikov, S., Lee, G. R., Wang, J., Cong, Q., Kinch, L. N., Schaeffer, R. D., et al. (2021) · doi:10.1101/2021.06.14.448402 · Cited by 5,549 · cited 1×
“18,19 Figure 1 presents a chronological overview of signi fi cant advancements and key events in PPI research and therapeutics.”
Tracey, K. J. (2002) · Nature · doi:10.1038/nature01321 · Cited by 3,728
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Towards a knowledge-based Human Protein Atlas
Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1210-1248 · Cited by 2,440
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 2×
“307,309 The development of sotorasib began with the discovery of the indole-based small molecule inhibitor 7 which was capable of occupying a previously unexploited cryptic pocket on the surface of K-RAS located at the S-IIP (Fig.”
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027 · cited 1×
“237 Meanwhile, cancer progression is promoted by the evasion of growth suppression which is realized by the neutralization of tumor-suppressive functions by PPI complexes such as MDM2 – p53 and CDK4 – pRB. 225 Oncogenic network reprogramming results in some PPIs contributing to speci fi c cancer…”
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879 · cited 1×
“139 Macrocycles are cyclic peptides created by joining the peptide chain into a ring structure and represent another therapeutic option for targeting PPIs.”
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“284,285 The RAS family acts as membrane-bound molecular switches when activated by guanine nucleotide exchange factors (GEFs) that promote the change from the inactive “ GDP-bound ” state to an active “ GTP-bound ” state.”
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Inflammatory and immune pathways in the pathogenesis of periodontal disease
Cekici, A., Kantarci, A., Hasturk, H., & Van Dyke, T. E. (2014) · Periodontology 2000 · doi:10.1111/prd.12002 · Cited by 1,415
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Gene co-expression analysis for functional classification and gene–disease predictions
van Dam, S., Võsa, U., van der Graaf, A., Franke, L., & de Magalhães, J. P. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbw139 · Cited by 995
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927 · cited 1×
“274,275 The disordered nature of MYC has directed effort toward fi nding alternate therapeutic options for MYC inhibition.”
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823 · cited 1×
“210,211 Together these non-covalent interactions establish a stable drug-protein complex which results in the inhibition of the activity of the target protein.”
Hot spots—A review of the protein–protein interface determinant amino‐acid residues
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21396 · Cited by 760
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669 · cited 1×
“125 This issue of an entropic penalty and low cellular uptake can be addressed by modifying the peptides and/or incorporating unnatural amino acids.”
Emerging methods in protein co-evolution
de Juan, D., Pazos, F., & Valencia, A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3414 · Cited by 607
Targeted protein degradation by PROTACs
Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599 · cited 1×
“172 173 – 175 This mechanism offers several advantages over small molecule therapeutics such as the need for lower drug dosage, reduction of potential off-target effects and the ability to overcome resistance mutations that typically render small molecule inhibitors ineffective.”
Inflammatory Response in the CNS: Friend or Foe?
Sochocka, M., Diniz, B. S., & Leszek, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0297-1 · Cited by 573
Inflammatory mechanisms: the molecular basis of inflammation and disease
Libby, P. (2007) · Nutrition Reviews · doi:10.1301/nr.2007.dec.s140-s146 · Cited by 560
X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Nair, S. K., & Burley, S. K. (2003) · Cell · doi:10.1016/s0092-8674(02)01284-9 · Cited by 551
Modulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497 · cited 2×
“27,28 Understanding the role of at least one interacting component aids in de fi ning its function and pathway within cells, with the mapping of these interactions unveiling the intricate nature of cross-connectivity and cellular pathways.”
Lochhead, J. J., Yang, J., Ronaldson, P. T., & Davis, T. P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00914 · Cited by 445
Inflammaging and Anti-Inflammaging: The Role of Cytokines in Extreme Longevity
Minciullo, P. L., Catalano, A., Mandraffino, G., Casciaro, M., Crucitti, A., Maltese, G., Morabito, N., Lasco, A., Gangemi, S., & Basile, G. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0377-3 · Cited by 433
Targeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401 · cited 1×
“225,226 229 PPIs are the fundamental elements within these signaling networks which makes them an ideal target for the development of targeted therapies that can disrupt these crucial interactions.”
Predicting Protein–Protein Interactions from the Molecular to the Proteome Level
Keskin, O., Tuncbag, N., & Gursoy, A. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00683 · Cited by 369 · cited 2×
“68,74,75 In addition to the traditional categorization, the computational methods employed for predicting PPIs can be further categorized based on the type of information utilized.”
Structure-based design of targeted covalent inhibitors
Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Bekaii-Saab, T. S., Yaeger, R., Spira, A. I., Pelster, M. S., Sabari, J. K., Hafez, N., Barve, M., Velastegui, K., Yan, X., Shetty, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00434 · Cited by 313 · cited 1×
“17,308 While both adagrasib and sotorasib are successful examples of drug development targeting the allosteric S-IIP, the greater availability of reported sotorasib derivatives and their respective biological activity when compared to adagrasib offers a more comprehensive understanding of its SARs…”
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312 · cited 1×
“108,109 This can often necessitate a modulator that covers a substantial surface area and establishes numerous hydrophobic contacts, a pro fi le that frequently introduces pharmacokinetic hurdles due to the large size and poor solubility of such moleules.”
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217730110 · Cited by 293
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases
Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Tubiana, J., Schneidman-Duhovny, D., & Wolfson, H. J. (2022) · Nature Methods · doi:10.1038/s41592-022-01490-7 · Cited by 274
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Nan, X., Tamgüney, T. M., Collisson, E. A., Lin, L.-J., Pitt, C., Galeas, J., Lewis, S., Gray, J. W., McCormick, F., & Chu, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509123112 · Cited by 273 · cited 1×
“287,288 While RAS oncoproteins share a similar overall structure, they are distinguished by their hypervariable regions (HVR).”
Blair, H. A. (2021) · Drugs · doi:10.1007/s40265-021-01574-2 · Cited by 241
Baran, P., Hansen, S., Waetzig, G. H., Akbarzadeh, M., Lamertz, L., Huber, H. J., Ahmadian, M. R., Moll, J. M., & Scheller, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001163 · Cited by 235
MutaBind2: predicting the impacts of single and multiple mutations on protein-protein interactions
Zhang, N., Chen, Y., Lu, H., Zhao, F., Alvarez, R. V., Goncearenco, A., Panchenko, A. R., & Li, M. (2020) · iScience · doi:10.1016/j.isci.2020.100939 · Cited by 199 · cited 1×
“98 The combination of computational methods such as MD simulations, docking and CAS provide a powerful tool for accelerating the identi fi cation process of hot spots within PPIs and pave the way for the development of targeted therapeutics through structure-based drug design.”
Carabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172 · cited 1×
“247,248 251 However, the approach of stabilizing Max homodimers is associated with unintended consequences on other Max functions.”
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165 · cited 1×
“46 Additionally, computer modeling techniques coupled with phage display technology has enabled the rational design of peptidomimetics that are designed to recapitulate the secondary structure of key peptide helices, sheets and loops within PPIs.”
Signaling networks determining life span
Riera, C. E., Merkwirth, C., De Magalhaes Filho, C. D., & Dillin, A. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014451 · Cited by 161
Dhillon, S. (2023) · Drugs · doi:10.1007/s40265-023-01839-y · Cited by 161
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Lise, S., Archambeau, C., Pontil, M., & Jones, D. T. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-365 · Cited by 107
Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
Hot-spot analysis for drug discovery targeting protein-protein interactions
Rosell, M., & Fernández-Recio, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1430763 · Cited by 105
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
Demma, M. J., Mapelli, C., Sun, A., Bodea, S., Ruprecht, B., Javaid, S., Wiswell, D., Muise, E., Chen, S., Zelina, J., et al. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00248-19 · Cited by 92
Computational Alanine Scanning Mutagenesis: MM-PBSA vs TI
Martins, S. A., Perez, M. A. S., Moreira, I. S., Sousa, S. F., Ramos, M. J., & Fernandes, P. A. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct4000372 · Cited by 72
Sijbesma, E., Visser, E., Plitzko, K., Thiel, P., Milroy, L.-G., Kaiser, M., Brunsveld, L., & Ottmann, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17741-0 · Cited by 72
Covalent Guanosine Mimetic Inhibitors of G12C KRAS
Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., Lim, S. M., Manandhar, A., Gondi, S., Sim, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00373 · Cited by 66
Protein–Protein Interaction Modulators for Epigenetic Therapies
(2018) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2017.06.002 · Cited by 31
Screening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
Giblin, K. A., Basili, D., Afzal, A. M., Rosenbrier-Ribeiro, L., Greene, N., Barrett, I., Hughes, S. J., & Bender, A. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00311 · Cited by 18 · cited 1×
“163,164 Meanwhile, immunogenicity refers to the development of anti-drug antibodies (ADAs) by the patient ’ s immune system in response to the therapeutic mAb.”
Cited by
ProteinDJ : A high‐performance and modular protein design pipeline
Silke, D., Iskander, J., Pan, J., Thompson, A. P., Papenfuss, A. T., Lucet, I. S., & Hardy, J. M. (2026) · Protein Science · doi:10.1002/pro.70464 · Cited by 6
AI-assisted design of ligands for lipocalin-2
Sgrignani, J., Buscarini, S., Locatelli, P., Guerra, C., Furlan, A., Chen, Y., Zoppi, G., & Cavalli, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631868 · Cited by 4
Nada, H., Yuan, S., Gaamouch, F. E., Cho, S., & Gabr, M. T. (2026) · doi:10.64898/2026.01.19.700278 · Cited by 3
“…have focused on an(cid:415)body-based TREM2 modula(cid:415)on which face the inherent challenge of restricted blood-brain barrier (BBB) penetra(cid:415)on, high produc(cid:415)on costs, immunogenicity risks and prolonged systemic half-lives that may extend immune-related adverse events 23 .”
Self-citation
Metadata
- Authors
- Nada, H., Choi, Y., Kim, S., Jeong, K. S., Meanwell, N. A., & Lee, K.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-12-06
- Volume
- 9
- Issue
- 1
- Pages
- 341-341
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4405035146
- Cited by
- 216
- References
- 67
- FWCI
- 25.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.